Hookipa Pharma (NASDAQ:HOOK) Given New $48.00 Price Target at Royal Bank of Canada

Hookipa Pharma (NASDAQ:HOOK) had its price objective cut by Royal Bank of Canada from $50.00 to $48.00 in a report released on Friday morning, Marketbeat Ratings reports. They currently have an outperform rating on the stock.

Separately, JMP Securities boosted their price objective on shares of Hookipa Pharma from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Friday, August 9th.

Hookipa Pharma Stock Down 4.5 %

HOOK stock traded down $0.14 during trading on Friday, hitting $3.00. The company had a trading volume of 95,565 shares, compared to its average volume of 57,184. The firm has a market capitalization of $36.18 million, a P/E ratio of -0.69 and a beta of 0.84. The company has a 50 day simple moving average of $4.09 and a 200-day simple moving average of $5.74. Hookipa Pharma has a 52-week low of $2.85 and a 52-week high of $11.30.

Hedge Funds Weigh In On Hookipa Pharma

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Hookipa Pharma during the first quarter worth $31,000. Ikarian Capital LLC purchased a new stake in Hookipa Pharma during the 3rd quarter worth approximately $228,000. Renaissance Technologies LLC lifted its holdings in Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after buying an additional 83,800 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. 63.88% of the stock is owned by hedge funds and other institutional investors.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.